Pembelian
Possible H&S, after FDA approval for fast track consideration?
The MACD and RSI looks a little overbought. Also the upcoming FDA approval, is not for usage of the drug. But just a Phase 3 fast track evaluation of the drug. Which would take another few months, before an actual approval.
Am expecting a likely correction, which I would buy in a bit more.
On the long term, am bullish of this drug and the tumour imaging agent, it has bought rights for.
Am expecting a likely correction, which I would buy in a bit more.
On the long term, am bullish of this drug and the tumour imaging agent, it has bought rights for.
Catatan
Looks like not much chance of a major correction, with more institutional investors coming in.Catatan
Seems like a correction till 2.20
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.